Endocrine Abstracts

The introduction of PCSK9 inhibitors has changed the paradigm of dyslipidemia treatment. These monoclonal antibodies produce an incremental LDL reduction of about 60% add-on current therapy. Achieving LDL concentrations below 40 mg/dl is usual. The recent publication on the effect of very low LDL concentrations on atherosclerotic plaque burden (Glagov study) and on cardiovascular outcomes (Fourier and Spire) show the impact of this therapy in cardiovascular prevention. In the other hand these treatments seem to be pretty safe. Ebbinhouse study has demonstrated no impact on neurocognitive function. Price of therapy is the main limiting factors and several scientific societies have issued recommendation for use. The aim of this meeting is discussing about the new approaches of dyslipidemia therapy.